A research group including Schally, among others, demonstrated the beneficial effect of LHRH analog treatment in patients with prostate cancer in 1982.35 The first LHRH analogs approved for commercial use in PC were buserelin and leuprolide in 1984.36 LHRH analogs remain one of the most commonly used alternatives for androgen deprivation therapy (ADT) in the treatment of PC to date. The gene discussed is GNRH1; the disease is pachyonychia congenita.